Madrigal Pharma (NASDAQ: MDGL) reported Q1 EPS of ($3.32), $0.54 better than the analyst estimate of ($3.86). Revenue for the quarter came in at $137.25 million versus the consensus estimate of $112.54 million.

For earnings history and earnings-related data on Madrigal Pharma (MDGL) click here.